Unilife — Q4 and FY2016 Earnings Presentation
19 slides from Unilife's earnings presentation, Nov 2, 2016
Slide 1: Industry-Leading Wearable Injectors, People and Partners
Industry-Leading Wearable Injectors, People and Partners November 2, 2016 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's
Slide 3: Agenda
Industry-Leading Wearable Injectors, People and Partners - Agenda John Ryan President and CEO Opening Remarks Update on Targeted Growth Strategy Michael Ratigan SVP and Chief Commercial Officer Wearable Injector Market Overview Ian Hanson SVP and Chief Operating Officer Unilife Portfolio of Wearable
Slide 4: Introduction
Introduction Industry-Leading Wearable Injectors, People and Partners An Attractive, Growing and Under-Served Market The Industry’s Best Wearable Injector Portfolio The Right People and Partners for Commercial Success
Slide 5: Targeted Growth Strategy: Attractive, Growing and Under-Served Market
Targeted Growth Strategy Industry-Leading Wearable Injectors, People and Partners Wearable injectors for delivery of biologics Large biopharma companies seek platform- based systems for use with multiple target drugs Platforms support effective lifecycle management of multiple target therapy brands
Slide 6: Targeted Growth Strategy: Industry's Best Wearable Injector Portfolio
Targeted Growth Strategy Industry-Leading Wearable Injectors, People and Partners The first pre-filled, pre-assembled wearable injector portfolio Fully integrated, ready-to-inject therapies Customers can expect unique therapy brand identity through use of wearable platforms An Attractive, Growing an
Slide 7: Targeted Growth Strategy: Right People and Partners
Targeted Growth Strategy Industry-Leading Wearable Injectors, People and Partners Talented team of engineers supported by disciplined leadership Focused on customer programs and path to commercial sales Rigorous cost controls and reduced cash burn Strategic collaboration with Amgen Strong partnershi
Slide 8: Strong, Disciplined Team
Mary Kate Wold, Chair Rosemary Crane Duane DeSisto Harry Hamill John Lund Jeff Carter John Ryan President and CEO David Hastings SVP and CFO Ian Hanson SVP and COO Michael Ratigan SVP, Chief Commercial Officer Stephanie Walters SVP, GC and Secretary Rick Bente VP, Combination Products VP Quality & R
Slide 9: Business Realigned for Disciplined Execution and Reduced Cash Burn
Targeted Growth Strategy Business Realigned for Disciplined Execution and Reduced Cash Burn Business Realigned for Execution on Wearable Programs Rigorous Cost Control Measures Reducing Operating Expenses Long-Term Relationships Workforce reduced – ↓53% Teams aligned for optimizing performance on pr
Slide 10: Engaged Workforce
Engaged Workforce ~ 70 operations employees engaged in manufacturing devices and sub-assemblies, and developing processes and equipment for customer programs ~ 50 engineers and technical staff designing and testing wearable devices to advance customer programs, and on continued product innovation >
Slide 11: Addressing Market Needs with Wearable Injectors
Addressing Market Needs with Wearable Injectors Improving Patient Experience to Optimize Therapy Compliance + + From E.g. 1mL every two weeks to 2mL every month E.g. Three injections per dose to 1 injection for full dose E.g. 180mg (1mL) in 10 sec. to 180mg (2mL) in 45 sec. Intuitive steps of use wi
Slide 12: Significant Market Opportunity
Significant Market Opportunity BioPharma Companies with Potential for Multiple Wearable Programs Over 100 phase II, III or marketed molecules from biopharma companies identified as having products with characteristics that make them potential candidates for prospective use with wearable or hand-held
Slide 13: Wearable Injectors – A Significant Market Opportunity
1st Wave 2nd Wave 3rd Wave Initial therapies launched in first generation wearable injector technologies Various pharma with multi-drug targets select preferred wearable platforms and partners Lead programs underway (avg. 3-4 yr. period from program start until commercial launch) Multiple pharma com
Slide 14: Unilife Wearable Injector Portfolio
Precision-Therapy™ Flex-Therapy™ Flex-Therapy™ Mini Imperium™ 0.5mL to 2mL 0.5mL to 2mL 2mL to 10mL 2mL to 10mL Constant basal insulin with on-demand bolus Any bolus, constant infusion or variable rate Immediate bolus Delayed or intermittent bolus, constant infusion or variable rate Electromechanica
Slide 15: Competitive Advantages
Unilife Wearable Injectors Competitor A Competitor B 3 Device-related steps to therapy 9 Device-related steps to therapy 9 Device-related steps to therapy Supplied to user pre-filled and fully integrated with drug in ready-to-inject format Supplied to user in kit for assembly and loading of dose int
Slide 16: Connected Health Ecosystems
Connected Health Ecosystems Enabling Drug, Device and Data Integration to Enhance Care Data Hub Delivery System with Integrated Connectivity Therapeutic App on Phone, Tablet or Computer Cloud-Based Hub for Data Access and Security Scanning of Drug by QR Code or RFID Bluetooth integrated in device Di
Slide 17: Selected Financial Results
Selected Financial Results Q4 2016 Q4 2015 FY 2016 FY 2015 Revenue $ 6.3M $ 3.5M $ 14.8M $ 13.2M Research & development (1) $ 7.4M $ 17.0M $ 43.2M $ 52.5M Selling, general & administrative (2) $ 7.6M $ 9.4M $ 43.2M $ 36.2M Net loss (3) ($7.7M) ($26.1M) ($100.8M) ($90.8M) Net loss per share – diluted
Slide 18: Targeted Growth Strategy Implemented
Targeted Growth Strategy Implemented Commence Supply for Clinical Trials Commence Commercial Scale-Up Commence Commercial Sales Continued Commercial Growth 2017 2018 2019 2016 Customer programs complete device design verification Production and supply of clinical batches for customers for human clin
Slide 19: Summary
Summary Focused on industry-leading wearable injector technology Long-term collaborations with large pharmaceutical companies: Amgen, AstraZeneca, and Sanofi Disciplined, experienced leadership focused on minimizing cash burn and becoming a profitable company Significant commercial opportunity for w